vs

Side-by-side financial comparison of Celanese Corp (CE) and Emerson Electric (EMR). Click either name above to swap in a different company.

Emerson Electric is the larger business by last-quarter revenue ($4.3B vs $2.2B, roughly 2.0× Celanese Corp). Emerson Electric runs the higher net margin — 13.9% vs 0.6%, a 13.3% gap on every dollar of revenue. On growth, Emerson Electric posted the faster year-over-year revenue change (4.1% vs -7.0%). Emerson Electric produced more free cash flow last quarter ($602.0M vs $168.0M). Over the past eight quarters, Emerson Electric's revenue compounded faster (-0.3% CAGR vs -8.1%).

Celanese Corporation, formerly known as Hoechst Celanese, is an American technology and specialty materials company headquartered in Irving, Texas. It is a Fortune 500 corporation. The company is the world's leading producer of acetic acid, producing about 1.95 million tonnes per year, representing approximately 20% of global production. Celanese is also the world's largest producer of vinyl acetate monomer (VAM).

Emerson Electric Co. is an American multinational corporation headquartered in St. Louis, Missouri. The Fortune 500 company delivers a range of engineering services, manufactures industrial automation equipment, climate control systems, and precision measurement instruments, and provides software engineering for industrial, commercial, and consumer markets.

CE vs EMR — Head-to-Head

Bigger by revenue
EMR
EMR
2.0× larger
EMR
$4.3B
$2.2B
CE
Growing faster (revenue YoY)
EMR
EMR
+11.1% gap
EMR
4.1%
-7.0%
CE
Higher net margin
EMR
EMR
13.3% more per $
EMR
13.9%
0.6%
CE
More free cash flow
EMR
EMR
$434.0M more FCF
EMR
$602.0M
$168.0M
CE
Faster 2-yr revenue CAGR
EMR
EMR
Annualised
EMR
-0.3%
-8.1%
CE

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
CE
CE
EMR
EMR
Revenue
$2.2B
$4.3B
Net Profit
$14.0M
$605.0M
Gross Margin
19.1%
53.2%
Operating Margin
4.0%
17.8%
Net Margin
0.6%
13.9%
Revenue YoY
-7.0%
4.1%
Net Profit YoY
100.7%
3.4%
EPS (diluted)
$0.13
$1.07

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CE
CE
EMR
EMR
Q4 25
$2.2B
$4.3B
Q3 25
$2.4B
$4.9B
Q2 25
$2.5B
$4.6B
Q1 25
$2.4B
$4.4B
Q4 24
$2.4B
$4.2B
Q3 24
$2.6B
$4.6B
Q2 24
$2.7B
$4.4B
Q1 24
$2.6B
$4.4B
Net Profit
CE
CE
EMR
EMR
Q4 25
$14.0M
$605.0M
Q3 25
$-1.4B
$637.0M
Q2 25
$199.0M
$586.0M
Q1 25
$-21.0M
$485.0M
Q4 24
$-1.9B
$585.0M
Q3 24
$116.0M
$996.0M
Q2 24
$155.0M
$329.0M
Q1 24
$121.0M
$501.0M
Gross Margin
CE
CE
EMR
EMR
Q4 25
19.1%
53.2%
Q3 25
21.5%
51.9%
Q2 25
21.1%
52.6%
Q1 25
19.9%
53.5%
Q4 24
22.7%
53.5%
Q3 24
23.5%
51.3%
Q2 24
24.2%
52.8%
Q1 24
21.2%
52.2%
Operating Margin
CE
CE
EMR
EMR
Q4 25
4.0%
17.8%
Q3 25
-52.7%
16.4%
Q2 25
9.2%
16.1%
Q1 25
7.0%
14.2%
Q4 24
-59.3%
18.6%
Q3 24
9.4%
14.7%
Q2 24
9.4%
10.4%
Q1 24
8.0%
16.2%
Net Margin
CE
CE
EMR
EMR
Q4 25
0.6%
13.9%
Q3 25
-56.1%
13.1%
Q2 25
7.9%
12.9%
Q1 25
-0.9%
10.9%
Q4 24
-80.8%
14.0%
Q3 24
4.4%
21.6%
Q2 24
5.8%
7.5%
Q1 24
4.6%
11.4%
EPS (diluted)
CE
CE
EMR
EMR
Q4 25
$0.13
$1.07
Q3 25
$-12.39
$1.12
Q2 25
$1.81
$1.04
Q1 25
$-0.19
$0.86
Q4 24
$-17.50
$1.02
Q3 24
$1.06
$1.74
Q2 24
$1.41
$0.57
Q1 24
$1.10
$0.87

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CE
CE
EMR
EMR
Cash + ST InvestmentsLiquidity on hand
Total DebtLower is stronger
$11.4B
$7.6B
Stockholders' EquityBook value
$4.0B
$20.3B
Total Assets
$21.7B
$41.9B
Debt / EquityLower = less leverage
2.81×
0.37×

8-quarter trend — quarters aligned by calendar period.

Total Debt
CE
CE
EMR
EMR
Q4 25
$11.4B
$7.6B
Q3 25
$11.7B
$8.9B
Q2 25
$12.7B
$8.3B
Q1 25
$12.4B
$8.2B
Q4 24
$11.1B
$6.6B
Q3 24
$11.3B
$7.7B
Q2 24
$11.1B
$7.1B
Q1 24
$11.0B
$7.6B
Stockholders' Equity
CE
CE
EMR
EMR
Q4 25
$4.0B
$20.3B
Q3 25
$4.0B
$20.3B
Q2 25
$5.3B
$19.9B
Q1 25
$5.2B
$19.2B
Q4 24
$5.2B
$20.5B
Q3 24
$7.3B
$21.6B
Q2 24
$7.2B
$20.8B
Q1 24
$7.1B
$20.9B
Total Assets
CE
CE
EMR
EMR
Q4 25
$21.7B
$41.9B
Q3 25
$22.2B
$42.0B
Q2 25
$23.7B
$42.5B
Q1 25
$23.2B
$42.0B
Q4 24
$22.9B
$42.6B
Q3 24
$25.9B
$44.2B
Q2 24
$25.8B
$45.6B
Q1 24
$26.0B
$46.4B
Debt / Equity
CE
CE
EMR
EMR
Q4 25
2.81×
0.37×
Q3 25
2.95×
0.44×
Q2 25
2.41×
0.42×
Q1 25
2.39×
0.42×
Q4 24
2.14×
0.32×
Q3 24
1.56×
0.36×
Q2 24
1.54×
0.34×
Q1 24
1.56×
0.36×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CE
CE
EMR
EMR
Operating Cash FlowLast quarter
$252.0M
$699.0M
Free Cash FlowOCF − Capex
$168.0M
$602.0M
FCF MarginFCF / Revenue
7.6%
13.9%
Capex IntensityCapex / Revenue
3.8%
2.2%
Cash ConversionOCF / Net Profit
18.00×
1.16×
TTM Free Cash FlowTrailing 4 quarters
$803.0M
$4.4B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CE
CE
EMR
EMR
Q4 25
$252.0M
$699.0M
Q3 25
$447.0M
$3.1B
Q2 25
$410.0M
$1.1B
Q1 25
$37.0M
$241.0M
Q4 24
$494.0M
$777.0M
Q3 24
$79.0M
$3.3B
Q2 24
$292.0M
$1.1B
Q1 24
$101.0M
$743.0M
Free Cash Flow
CE
CE
EMR
EMR
Q4 25
$168.0M
$602.0M
Q3 25
$383.0M
$2.7B
Q2 25
$317.0M
$977.0M
Q1 25
$-65.0M
$154.0M
Q4 24
$389.0M
$694.0M
Q3 24
$-9.0M
$2.9B
Q2 24
$187.0M
$998.0M
Q1 24
$-36.0M
$661.0M
FCF Margin
CE
CE
EMR
EMR
Q4 25
7.6%
13.9%
Q3 25
15.8%
54.9%
Q2 25
12.5%
21.5%
Q1 25
-2.7%
3.5%
Q4 24
16.4%
16.6%
Q3 24
-0.3%
63.1%
Q2 24
7.1%
22.8%
Q1 24
-1.4%
15.1%
Capex Intensity
CE
CE
EMR
EMR
Q4 25
3.8%
2.2%
Q3 25
2.6%
8.9%
Q2 25
3.7%
2.0%
Q1 25
4.3%
2.0%
Q4 24
4.4%
2.0%
Q3 24
3.3%
9.1%
Q2 24
4.0%
2.1%
Q1 24
5.2%
1.9%
Cash Conversion
CE
CE
EMR
EMR
Q4 25
18.00×
1.16×
Q3 25
4.86×
Q2 25
2.06×
1.83×
Q1 25
0.50×
Q4 24
1.33×
Q3 24
0.68×
3.35×
Q2 24
1.88×
3.31×
Q1 24
0.83×
1.48×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CE
CE

Engineered Materials$1.3B58%
Acetyl Chain$940.0M43%

EMR
EMR

Other$1.8B41%
Software And Systems$1.0B24%
Intelligent Devices$996.0M23%
Safety And Productivity$503.0M12%

Related Comparisons